Business Description
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
ISIN : US30233M1071
Total Employee Number:
13Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 37.19 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 74.2 | |||||
3-Year EPS without NRI Growth Rate | 76.3 | |||||
3-Year FCF Growth Rate | 73.4 | |||||
3-Year Book Growth Rate | -57.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 11.25 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.68 | |||||
Quick Ratio | 6.68 | |||||
Cash Ratio | 4.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -165.9 | |||||
Shareholder Yield % | -2.58 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -56.26 | |||||
ROA % | -39.13 | |||||
ROIC % | -138.56 | |||||
3-Year ROIIC % | -41.05 | |||||
ROC (Joel Greenblatt) % | -3488.32 | |||||
ROCE % | -50.65 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.34 | |||||
PB Ratio | 0.76 | |||||
Price-to-Tangible-Book | 0.9 | |||||
EV-to-EBIT | 0.14 | |||||
EV-to-EBITDA | 0.14 | |||||
EV-to-Forward-Revenue | 0.56 | |||||
EV-to-FCF | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 0.94 | |||||
| Price-to-Net-Cash | 1.62 | |||||
Earnings Yield (Greenblatt) % | 714.29 | |||||
FCF Yield % | -89.08 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiora Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.327 | ||
| Beta | 0.1091 | ||
| 3-Year Sharpe Ratio | -0.9 | ||
| 3-Year Sortino Ratio | -0.9 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 0.4208 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 0.4208 - 0.4208 | ||
| Shares Outstanding (Mil) | 4.43 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiora Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiora Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 126 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| General meeting for 2026 | 2026-06-10 13:00 | 0.42 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-08 07:00 | 0.42 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 07:00 | 0.42 (+0.00%) | ||
| Annual report for 2025 | 2026-03-25 | 0.42 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-07 | 0.42 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-08 | 0.42 (+0.00%) | ||
| General meeting for 2025 | 2025-06-04 10:00 | 0.42 (+0.00%) | ||
| First quarter earnings results for 2025 | 2025-05-09 | 0.42 (+0.00%) |
Show
Entries
Kiora Pharmaceuticals Inc Frequently Asked Questions
What is Kiora Pharmaceuticals Inc(FRA:7EY)'s stock price today?
The current price of FRA:7EY is €0.42. The 52 week high of FRA:7EY is €0.42 and 52 week low is €0.42.
When is next earnings date of Kiora Pharmaceuticals Inc(FRA:7EY)?
The next earnings date of Kiora Pharmaceuticals Inc(FRA:7EY) is 2026-08-07 Est..
Does Kiora Pharmaceuticals Inc(FRA:7EY) pay dividends? If so, how much?
Kiora Pharmaceuticals Inc(FRA:7EY) does not pay dividend.
Press Release
Articles on Kiora Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers